SCHEMBL26590303

SCHEMBL26590303

CC(C)(C)OC(=O)N1CC2(C1)CN(c1ncc(Br)cc1[N+](=O)[O-])C2

nearest known ligand 0.41

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
KCNH2 Q12809 1/20 0.41
EGLN2 Q96KS0 1/20 0.40
ALDH1A1 P00352 2/20 0.39
LMNA P02545 1/20 0.39
MAPT P10636 1/20 0.39
MET P08581 1/20 0.39
GPR119 Q8TDV5 4/20 0.39
RET P07949 2/20 0.37
NR1H2 P55055 1/20 0.36
CYP11B2 P19099 1/20 0.36
ACACB O00763 5/20 0.36
MAPK1 P28482 1/20 0.36
HTT P42858 1/20 0.36
OPRK1 P41145 1/20 0.35
EIF2AK4 Q9P2K8 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29968748 1.00 KCNH2 (0.41) KCNH2EGLN2ALDH1A1LMNAMAPT
SCHEMBL30323005 0.86 ALDH1A1 (0.52) KCNH2ALDH1A1LMNAMAPTMET
SCHEMBL22712090 0.86 ALDH1A1 (0.52) KCNH2ALDH1A1LMNAMAPTMET
SCHEMBL26131907 0.83 ALDH1A1 (0.40) ALDH1A1LMNAMAPTMAPK1HTT
SCHEMBL26590306 0.83 PDE10A (0.41) KCNH2ALDH1A1LMNAMAPTMET
SCHEMBL29969656 0.83 PDE10A (0.41) KCNH2ALDH1A1LMNAMAPTMET
SCHEMBL29970093 0.79 GPR119 (0.40) KCNH2ALDH1A1GPR119RETMAPK1
SCHEMBL25447173 0.77 GPR119 (0.54) EGLN2MAPTGPR119RETNR1H2
SCHEMBL28675410 0.77 GPR119 (0.46) KCNH2ALDH1A1LMNAMAPTMET
SCHEMBL29503589 0.77 GPR119 (0.46) KCNH2ALDH1A1LMNAMAPTMET

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4327877-A2 DUAL ATM AND DNA-PK INHIBITORS FOR USE IN ANTI-TUMOR THERAPY XRad Therapeutics, Inc. (US) 2024-02-28 EP disclosed
EP-3784671-B1 DUAL ATM AND DNA-PK INHIBITORS FOR USE IN ANTI-TUMOR THERAPY XRAD THERAPEUTICS INC (US) 2023-10-11 EP disclosed